Page last updated: 2024-11-11

ggti 2147

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9890888
CHEMBL ID27518
SCHEMBL ID10018886
MeSH IDM0440319

Synonyms (14)

Synonym
(s)-2-{4-[(1h-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzoylamino}-4-methyl-pentanoic acid methyl ester
bdbm50076139
ggti-2147
ggti 2147
CHEMBL27518 ,
ggti2147
geranylgeranyl transferase inhibitor-2147
SCHEMBL10018886
191102-87-1
l-leucine, n-(4-((1h-imidazol-4-ylmethyl)amino)-2-(1-naphthalenyl)benzoyl)-, methyl ester
methyl (4-(((1h-imidazol-4-yl)methyl)amino)-2-(naphthalen-1-yl)benzoyl)-l-leucinate
methyl (2s)-2-[[4-(1h-imidazol-5-ylmethylamino)-2-naphthalen-1-ylbenzoyl]amino]-4-methylpentanoate
methyl (4-(((1h-imidazol-5-yl)methyl)amino)-2-(naphthalen-1-yl)benzoyl)-l-leucinate
AKOS040746855
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)30.00000.00020.75218.0140AID132512
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaMus musculus (house mouse)IC50 (µMol)30.00001.00001.00001.0000AID132512
Protein farnesyltransferase subunit betaMus musculus (house mouse)IC50 (µMol)30.00001.00001.00001.0000AID132512
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID164445In vitro inhibition of [3H]GGPP incorporation into H-Ras-CVLL by Geranylgeranyl transferase type I (Not determined)1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
AID72815In vitro inhibition of [3H]FPP incorporation into H-Ras-CVLS by Farnesyl transferase (Not determined)1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
AID132512In vivo for inhibition of farnesylation based on the inhibition of H-Ras processing.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
AID132514In vivo inhibition of geranylgeranylation based on the inhibition of Rap1A processing.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's5 (50.00)29.6817
2010's4 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.78 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]